Achmea Investment Management’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-526,616
| Closed | -$13.4M | – | 259 |
|
|
2025
Q3 | $13.4M | Buy |
526,616
+201,826
| +62% | +$4.98M | 0.17% | 149 |
|
|
2025
Q2 | $7.87M | Buy |
324,790
+12,888
| +4% | +$301K | 0.1% | 187 |
|
|
2025
Q1 | $7.9M | Buy |
311,902
+205,886
| +194% | +$5.39M | 0.12% | 184 |
|
|
2024
Q4 | $2.81M | Buy |
+106,016
| New | +$2.88M | 0.05% | 264 |
|
|
2024
Q2 | – | Sell |
-198,587
| Closed | -$5.51M | – | 428 |
|
|
2024
Q1 | $5.51M | Sell |
198,587
-134,704
| -40% | -$3.74M | 0.11% | 205 |
|
|
2023
Q4 | $9.6M | Sell |
333,291
-258,413
| -44% | -$7.81M | 0.2% | 131 |
|
|
2023
Q3 | $19.6M | Sell |
591,704
-252,826
| -30% | -$8.94M | 0.43% | 50 |
|
|
2023
Q2 | $31M | Buy |
844,530
+114,317
| +16% | +$4.45M | 0.65% | 28 |
|
|
2023
Q1 | $29.8M | Buy |
730,213
+81,639
| +13% | +$3.53M | 0.86% | 18 |
|
|
2022
Q4 | $31.1M | Buy |
648,574
+9,530
| +1% | +$457K | 1.04% | 17 |
|
|
2022
Q3 | $28M | Sell |
639,044
-51,069
| -7% | -$2.48M | 0.99% | 17 |
|
|
2022
Q2 | $36.2M | Sell |
690,113
-3,380
| -0.5% | -$172K | 1.17% | 13 |
|
|
2022
Q1 | $35.9M | Buy |
+693,493
| New | +$36M | 0.94% | 16 |
|
|
2021
Q4 | – | Sell |
-494,314
| Closed | -$21.3M | – | 484 |
|
|
2021
Q3 | $21.3M | Buy |
494,314
+24,068
| +5% | +$1.07M | 0.65% | 24 |
|
|
2021
Q2 | $18.4M | Sell |
470,246
-9,842
| -2% | -$383K | 0.63% | 26 |
|
|
2021
Q1 | $17.4M | Buy |
480,088
+74,062
| +18% | +$2.63M | 0.61% | 30 |
|
|
2020
Q4 | $14.9M | Buy |
406,026
+16,573
| +4% | +$608K | 0.54% | 34 |
|
|
2020
Q3 | $13.6M | Buy |
+389,453
| New | +$13.7M | 0.57% | 34 |
|
|
2020
Q1 | – | Sell |
-474,206
| Closed | -$17.6M | – | 474 |
|
|
2019
Q4 | $17.6M | Sell |
474,206
-152,809
| -24% | -$5.44M | 0.68% | 28 |
|
|
2019
Q3 | $21.4M | Sell |
627,015
-252,501
| -29% | -$9.18M | 0.84% | 25 |
|
|
2019
Q2 | $36.1M | Sell |
879,516
-65,594
| -7% | -$2.6M | 1.38% | 10 |
|
|
2019
Q1 | $38.1M | Sell |
945,110
-40,734
| -4% | -$1.63M | 1.59% | 9 |
|
|
2018
Q4 | $40.8M | Buy |
985,844
+3,362
| +0.3% | +$140K | 1.89% | 6 |
|
|
2018
Q3 | $41.1M | Sell |
982,482
-194,578
| -17% | -$7.49M | 1.56% | 8 |
|
|
2018
Q2 | $40.5M | Buy |
1,177,060
+64,820
| +6% | +$2.22M | 1.42% | 10 |
|
|
2018
Q1 | $37.4M | Buy |
1,112,240
+94,981
| +9% | +$3.27M | 1.26% | 9 |
|
|
2017
Q4 | $35M | Buy |
1,017,259
+477,823
| +89% | +$16.3M | 1.18% | 13 |
|
|
2017
Q3 | $18.3M | Buy |
539,436
+11,664
| +2% | +$375K | 1.04% | 19 |
|
|
2017
Q2 | $16.8M | Sell |
527,772
-257,948
| -33% | -$8.13M | 1.01% | 17 |
|
|
2017
Q1 | $25.5M | Buy |
+785,720
| New | +$24.8M | 1.2% | 14 |
|
Other funds holding PFE
Achmea Investment Management's PFE Position: Q4 2025 in Review
Achmea Investment Management sold out of Pfizer (PFE) in Q4 2025, closing a stake of 526,616 shares — an estimated $13.4M sold.
Achmea Investment Management first reported a position in PFE in Q1 2017 and held it in 30 quarters. The position peaked at $41.1M in Q3 2018. 2,905 funds tracked by Wall St. Rank hold PFE as of Q4 2025.
- Achmea Investment Management reported no remaining Pfizer position as of Q4 2025 after selling out during the quarter.
- Achmea Investment Management sold 526,616 Pfizer shares in Q4 2025, an estimated $13.4M.
- Achmea Investment Management first reported a position in Pfizer in Q1 2017 and held it in 30 quarters.
- Achmea Investment Management's Pfizer position peaked at $41.1M in Q3 2018.
- 2,905 funds tracked by Wall St. Rank held Pfizer as of Q4 2025.
Based on Achmea Investment Management's 13F filing for Q4 2025, filed 18 Feb 2026.